Obesity
The Obesity pipeline: 117 tracked drugs, 9 approved for this indication.
9 approved / phase 434 Phase 31 Phase 2/338 Phase 27 Phase 1/224 Phase 14 preclinical / unstaged
Compare the share prices of listed companies in Obesity →
Total attributable cost
$199.1B
$1,861/patient
Drug spend
$21.2B
$198/patient
BMI >=30 (or >=27 with a weight-related comorbidity) · US
The Obesity pipeline
Key trial results for every approved and late-stage drug: Obesity results by drug.